Senator Evan J. Vickers proposes the following substitute bill:


1     
PRESCRIPTION COST AMENDMENTS

2     
2022 GENERAL SESSION

3     
STATE OF UTAH

4     
Chief Sponsor: Evan J. Vickers

5     
House Sponsor: ____________

6     

7     LONG TITLE
8     General Description:
9          This bill enacts provisions relating to cost sharing for certain prescription drugs.
10     Highlighted Provisions:
11          This bill:
12          ▸     prohibits a health benefit plan from excluding payments made on behalf of an
13     insured when determining whether the insured has satisfied the plan's cost sharing
14     requirements.
15     Money Appropriated in this Bill:
16          None
17     Other Special Clauses:
18          None
19     Utah Code Sections Affected:
20     ENACTS:
21          31A-22-657, Utah Code Annotated 1953
22     

23     Be it enacted by the Legislature of the state of Utah:
24          Section 1. Section 31A-22-657 is enacted to read:
25          31A-22-657. Application of certain payments made on behalf of an insured to cost

26     sharing requirements.
27          (1) As used in this section:
28          (a) (i) "Cost sharing requirement" means copayments, coinsurance, deductibles, and
29     other requirements for payment an insured is required to make under the provisions of a health
30     benefit plan.
31          (ii) "Cost sharing requirement" does not include premiums.
32          (b) "Generic equivalent" means a drug product that is designated in the Approved Drug
33     Products with Therapeutic Equivalence Evaluations prepared by the Center for Drug
34     Evaluation and Research of the United States Food and Drug Administration as:
35          (i) the therapeutic equivalent of another drug product; and
36          (ii) an "A" rated drug product.
37          (c) "Manufacturer" means the same as that term is defined in Section 31A-48-102.
38          (d) "Qualified prescription drug" means a prescription drug, as defined in Section
39     58-17b-102, that is covered by the insurer under the insured's health benefit plan and for which:
40          (i) there is no generic equivalent or interchangeable biological product, as defined in
41     Section 58-17b-605.5;
42          (ii) there is no covered drug in the same therapeutic class used to treat the insured's
43     condition that is preferred under a formulary for the insured's health benefit plan; or
44          (iii) if applicable to the prescription drug under the insured's health benefit plan, the
45     insured has:
46          (A) received preauthorization from the health benefit plan for the prescription drug in
47     accordance with Section 31A-22-650;
48          (B) completed the health benefit plan's step therapy protocol or other utilization
49     management requirement for the prescription drug; or
50          (C) received authorization for the prescription drug as the result of an internal or
51     independent review in accordance with Section 31A-22-629.
52          (2) For a plan entered into or renewed on or after January 1, 2023, when determining
53     whether an insured has satisfied a health benefit plan's cost sharing requirement, the health
54     benefit plan may not exclude payments made on behalf of the insured for a qualified
55     prescription drug.
56          (3) Notwithstanding Subsection (2), if application of Subsection (2) would result in

57     health savings account ineligibility under 26 U.S.C. Sec. 223, payments made on behalf of an
58     insured for a qualified prescription drug that is not preventive care under 26 U.S.C. Sec.
59     223(c)(2)(C) shall apply to the insured's health savings account-qualified high deductible health
60     plan cost sharing requirement only after the insured has satisfied the health benefit plan's
61     deductible.